Steven Leonard Chapman Sells 5,370 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRAGet Rating) CEO Steven Leonard Chapman sold 5,370 shares of the firm’s stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $223,177.20. Following the completion of the sale, the chief executive officer now owns 103,779 shares in the company, valued at $4,313,055.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Steven Leonard Chapman also recently made the following trade(s):

  • On Tuesday, January 3rd, Steven Leonard Chapman sold 8,212 shares of Natera stock. The shares were sold at an average price of $39.55, for a total transaction of $324,784.60.
  • On Wednesday, December 28th, Steven Leonard Chapman sold 2,605 shares of Natera stock. The shares were sold at an average price of $39.84, for a total transaction of $103,783.20.
  • On Friday, December 23rd, Steven Leonard Chapman sold 1,660 shares of Natera stock. The shares were sold at an average price of $42.30, for a total transaction of $70,218.00.
  • On Wednesday, December 7th, Steven Leonard Chapman sold 2,645 shares of Natera stock. The shares were sold at an average price of $38.31, for a total transaction of $101,329.95.

Natera Stock Performance

NTRA opened at $42.94 on Wednesday. Natera, Inc. has a 12-month low of $26.10 and a 12-month high of $74.82. The company has a current ratio of 3.10, a quick ratio of 2.95 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $4.19 billion, a PE ratio of -7.56 and a beta of 1.28. The firm has a 50 day moving average of $39.55 and a two-hundred day moving average of $44.06.

Natera (NASDAQ:NTRAGet Rating) last issued its quarterly earnings data on Tuesday, November 8th. The medical research company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.17. The business had revenue of $210.64 million for the quarter, compared to analysts’ expectations of $208.31 million. Natera had a negative net margin of 70.34% and a negative return on equity of 109.07%. On average, analysts anticipate that Natera, Inc. will post -5.64 EPS for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several research analyst reports. BTIG Research decreased their price objective on shares of Natera from $95.00 to $75.00 in a research report on Wednesday, November 9th. Credit Suisse Group decreased their price objective on shares of Natera from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Monday, November 14th. Raymond James raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $58.00 price objective for the company in a research report on Wednesday, January 18th. Stephens decreased their price objective on shares of Natera to $67.00 in a research report on Wednesday, November 16th. Finally, Robert W. Baird decreased their price objective on shares of Natera from $72.00 to $65.00 in a research report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $80.00.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. Bank of New York Mellon Corp grew its stake in shares of Natera by 6.7% during the 1st quarter. Bank of New York Mellon Corp now owns 820,974 shares of the medical research company’s stock worth $33,399,000 after purchasing an additional 51,791 shares during the period. US Bancorp DE grew its stake in shares of Natera by 20.0% during the 1st quarter. US Bancorp DE now owns 16,180 shares of the medical research company’s stock worth $658,000 after purchasing an additional 2,698 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Natera by 215.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock worth $83,000 after purchasing an additional 1,399 shares during the period. Bank of Montreal Can grew its stake in shares of Natera by 80.6% during the 1st quarter. Bank of Montreal Can now owns 130,062 shares of the medical research company’s stock worth $5,390,000 after purchasing an additional 58,049 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in shares of Natera during the 1st quarter worth approximately $209,000. Institutional investors and hedge funds own 93.81% of the company’s stock.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Articles

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.